Department: Pharmaceutics and Pharmaceutical technology Semester: 1<sup>st</sup> **Program: MSc.** 



Academic year: 2024-2025

# **Course Plan**

### **First: Course Information**

| Course Name           | ourse Name:   |  | <b>Regulatory Affairs and Intellectual</b><br>property |         |   |           | 4  |  |
|-----------------------|---|--|--|---------|---|-----------|----|--|
| Credit Hours          | :   | 2  | Theoretical  | 2       |   | Practical | NA |  |
| Prerequisit           | <i>ite:</i> Class Number: Section 2   |  | Class Number: Section 2                                |         | Lecture Time : Monday<br>(16:30-17:30), (17:30-18:3 |           | •  |  |
| Level in JNQ          | F   | 9  | Virtual hours in th                                    | he JNQF | 80 1  | 80 hrs    |    |  |
| Course<br>Nature:     | $\square M$   | Mandatory Faculty RequirementImage: Optional University RequirementMandatory University RequirementFaculty RequirementAncillary CourseOptional Specialty RequirementMandatory Specialization requirement |  |         |   |           |    |  |
| Type of<br>Education: | <ul> <li><i>n</i>:</li> <li>Fully Face-to-Face Education</li> <li>Blended Education (3 Face-to-Face + 1 Asynchronous)</li> <li>Electronic Education Fully (1 Asynchronous + 2 Synchronous)</li> </ul> |  |  |         |   |           |    |  |

## Second: Instructor's Information

| Course coordinator:      |  |                     |                           |  |  |  |  |  |
|--------------------------|--|---------------------|---------------------------|--|--|--|--|--|
| Name: Dr. Marwan Shalash |  | Office Number: 212D | Email: mshalash@zu.edu.jo |  |  |  |  |  |
| Instructor:              | Instructor:  |                     |                           |  |  |  |  |  |
| Name: Dr. Marwan Shalash | Name: Dr. Marwan ShalashOffice Number: 212DEmail: mshalash@zu.edu.jo |                     |                           |  |  |  |  |  |
| Office Hours:            | Sunday, Monday, Tuesday, Wednesday and Thursday<br>(10:00-11:00)     |                     |                           |  |  |  |  |  |



#### **Third: Short Description of the Course**

This course provides an in-depth exploration of the regulatory affairs in the pharmaceutical industry, focusing on standards, guidelines, development, approval, protection, and lifecycle for ensuring of pharmaceutical products safety, efficacy, and quality. Students will learn about regulatory agencies frameworks and submission requirements such as Jordan food and drug admiration (JFDA) and other global authorities , In addition, the course will explore the various aspects of intellectual property (IP) rights relevant to the pharmaceutical sector. Students will learn about IP strategy development, licensing agreements, patents, trademarks, copyrights, and trade secrets, and how these IP assets can be strategically utilized to protect innovation and secure market exclusivity. Topics include regulatory submissions, clinical trials oversight, Good Manufacturing Practices (GMP), labeling requirements, and pharmacovigilance.

By the end of this course, students will be equipped with the knowledge and skills necessary to effectively manage regulatory affairs and intellectual property matters within the pharmaceutical industry. They will be able to prepare and submit a quality regulatory dossiers, and protect their organization's intellectual property assets.

### Fourth: Course objectives

1- Understand Regulatory Frameworks: To provide students a knowledge of the regulations and guidelines from major regulatory bodies (FDA, EMA, JFDA) affecting pharmaceuticals globally.

**2- Learn Drug Development Processes:** To teach students the stages of drug development, and the drug approval process which includes preclinical and clinical testing, Investigational New Drug Applications (IND), New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs) submissions. Post-marketing surveillance, detailing the regulatory requirements, documentation, and submission processes involved. Students will learn about Good Manufacturing Practices (GMP), and the importance of regulatory compliance throughout these phases. Emphasis will be placed on understanding the required documentation and data integrity standards.

#### 3- Develop Regulatory Submission Skills:

Prepare comprehensive regulatory submissions, including the Common Technical Document (CTD), ensuring compliance with applicable guidelines

**4- Intellectual Property Fundamentals** : Students will explore the fundamentals of intellectual property (IP) as it pertains to pharmaceuticals, including patents, trademarks, copyrights, and trade secrets. The course will cover how IP rights are established, maintained, and enforced in different jurisdictions.

#### 5- Analyze Case Studies and Practical Applications

To engage in case studies and real-world examples to apply theoretical knowledge to practical scenarios and solutions in pharmaceutical regulatory affairs and intellectual property management

#### 6- Good Regulatory Practices (GRPs):

Impart fundamental knowledge on various **Good Regulatory Practices** (**GRPs**) such as Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), and Good Clinical Practices (GCP) relevant to pharmaceutical production



|   | Fifth: Learning Outcomes |  |   |  |  |   |  |  |  |  |  |
|---|--------------------------|--|---|--|--|---|--|--|--|--|--|
| Level<br>descriptor<br>according to<br>(JNQF) | CILOs<br>Code            | <b>CILOs</b><br>If any CLO will not be assessed in the course,<br>mark NA.   | Associated<br>PILOs<br>Code<br>Choose one<br>PILO for each<br>CILO* | Assessment<br>method<br>Choose at least<br>two methods | Scores out of<br>100<br>State the total score<br>identified for each<br>CILO** | Minimum acceptable<br>Score/percentage (%)<br>The percentage should not be less<br>than 50% *** |  |  |  |  |  |
|   | K1                       | Comprehend knowledge and overview<br>of the regulatory aspects and<br>international guidelines related to the<br>quality, safety, and efficacy of products<br>in the pharmaceutical industry.  |   | Final exam   | 20   | 15 (75%)  |  |  |  |  |  |
| Knowledge                                     | K2                       | Explain the roles and regulations of<br>various regulatory bodies, such as<br>JFDA, FDA, and EMA, in the approval<br>process for pharmaceuticals, medical<br>devices, and other products, including<br>the relevant laws, guidelines, and<br>processes that govern product<br>development, manufacturing, and<br>registration. | Р. К2   | Final exam   | 15   | 11.25 (75%)   |  |  |  |  |  |
|   | К3                       | Describe the concepts, principles, and<br>regulations surrounding intellectual<br>property (IP) landscapes, including<br>patents, trademarks, copyrights, and<br>trade secrets, as they relate to national<br>and international laws in the<br>pharmaceutical industry   | tual<br>ling<br>and<br>onal   | Final exam   | 5  | 3.75 (75%)  |  |  |  |  |  |



|              | S1         | Practice the main regulations and<br>guidelines for the development,<br>manufacturing, approval, dossier<br>submission processes of pharmaceutical<br>products and medical devices.                       |       | - Final Exam<br>- Quizzes<br>-Assignment | 30 | 22.5 (75%) |
|--------------|------------|---|-------|--|----|------------|
| Skills       | <b>S</b> 2 | Retrieve the specific regulations, laws,<br>and guidelines for protecting<br>intellectual property related to<br>pharmaceutical products, including<br>patent searches, trademarks, and trade<br>secrets. | P. S2 | - Final Exam<br>- Quizzes<br>-Assignment | 10 | 7.5 (75%)  |
| Competencies | C1         | Implement the registration process<br>and its related aspects in<br>pharmaceutical product<br>development, manufacturing, and<br>approvals, in accordance with<br>regulations and guidelines.             | P. C2 | Assignment,<br>Presentation              | 20 | 15 (75%)   |

\*Refer to document (CC-2023-02) and page 2 in document (CC-2023-01)
\*\* Refer to document (CC-2023-05)
\*\*\*75% of the students must achieve the minimal acceptable percentage or higher for each CILO



Issue Date:11/7/2021

## Sixth: Learning Source

| Designated Book1:                               | Regulatory Affairs in the Pharmaceutical<br>Industry                  |              |  |  |  |
|---|---|--------------|--|--|--|
| <i>Author:</i><br>Javed Ali, Sanjula<br>Baboota | Print: 2022 version   | Year:2022    |  |  |  |
| Designated Book 2:                              | <b>Basics of Regulatory Affairs for Pharma</b><br><b>Professional</b> |              |  |  |  |
| <i>Author:</i><br>Dr. Jayesh Dhalani            | Print: 2019   | Year:2019    |  |  |  |
| Additional Sources:<br>Website:                 | JFDA, FDA , ICH Guidelines, GMPs, GDP and GL                          | P Guidelines |  |  |  |
| Teaching Type:                                  | Classroom   Laboratory  Workshop  MS Teams  Moodle                    |              |  |  |  |

| Seventh: Course Structure |  |                         |  |                  |   |  |  |  |
|---------------------------|--|-------------------------|--|------------------|---|--|--|--|
| Lecture Date              | Topics   | Teaching<br>Procedures* | Teaching<br>Methods**                                      | Covered<br>CILOs | References***<br>Principles of<br>Instrumental<br>Analysis, Seventh<br>Edition – By Skoog |  |  |  |
| Week 1                    | Overview   |                         |  |                  |   |  |  |  |
|                           | Pharmaceutical   | Online                  |  | K1, K2           | ICH, FDA  |  |  |  |
|                           | Industry   |                         |  |                  |   |  |  |  |
| Week 2                    | Introduction to<br>Pharmaceutical<br>Regulatory Affairs and<br>global Regulatory | Online                  |  | K1, K2           | ICH, FDA  |  |  |  |
|                           | Landscape  |                         | • Direct   |                  |   |  |  |  |
| Week 3                    | Drug Development<br>Process Overview   | Online                  | teaching<br>• Teaching                                     | K1, K2, S1       | ICH, FDA  |  |  |  |
| Week 4                    | ANDA and Generic<br>Drug Approval  | Online                  | through<br>discussion                                      | K1, K2, S1       | FDA   |  |  |  |
| Week 5                    | Regulatory<br>Documentation and<br>Submissions                                   | Online                  | <ul> <li>Problem<br/>solving based<br/>teaching</li> </ul> | K1, K2, S1       | JFDA, FDA   |  |  |  |
| Week 6                    | Regulatory<br>Documentation and<br>Submissions                                   | Online                  |  | K1, K2, S1, S2   | GDP, FDA  |  |  |  |
| Week 7                    | Global Drug<br>Development and<br>Harmonization                                  | Online                  |  | K1, K2, S1       | FDA   |  |  |  |
| Week 8                    | JFDA and GCC<br>requirements   | Online                  |  | K1, K2, S1,C1    | JFDA  |  |  |  |



issue:02

Issue Date:11/7/2021

| Week 9  | CTD and eCTD<br>Submissions                                    | Online |  | K1, K2, S1, C1 | JFDA   |
|---------|--|--------|--|----------------|--|
| Week 10 | Introduction to<br>Intellectual Property in<br>Pharma industry | Online | • Direct<br>teaching   | K1, K3, S2     | Regulatory<br>Affairs in the<br>Pharmaceutical<br>Industry |
| Week 11 | Fundamentals of<br>Intellectual Property in<br>Pharma industry | Online | <ul> <li>Teaching<br/>through<br/>discussion</li> <li>Problem</li> </ul> | K2, S2         | Regulatory<br>Affairs in the<br>Pharmaceutical<br>Industry |
| Week 12 | Introduction to<br>Pharmaceutical Patent                       | Online | solving based<br>teaching  | K2, S2         | Regulatory<br>Affairs in the<br>Pharmaceutical<br>Industry |
| Week 13 | Pharmaceutical Patent<br>management and<br>strategies          | Online |  | K2, S2, C1     | Regulatory<br>Affairs in the<br>Pharmaceutical<br>Industry |

\*Education procedures: (Direct, synchronous, asynchronous) \*\* Refer to document (CC-2023-04)

\*\*\*Reference: Pages of the book, number of the chapter, recorded lecture, video....)



## **Eighth: Assessment methods**

| Methods             | Fully<br>Electronic | Blended<br>Teaching | Direct<br>Teaching | Specific Course Output to be measured<br>*State the score identified for each CILO for each method of assessment out of 100<br>**If any CILO will not be assessed in the course, mark NA. |    |    |           |    |    |  |
|---------------------|---------------------|---------------------|--------------------|---|----|----|-----------|----|----|--|
|                     | Education           | tion                | 0                  | К1  | К2 | КЗ | <b>S1</b> | S2 | C1 |  |
| *Mid-term           |                     |                     |                    |   |    |    |           |    |    |  |
| Exam                |                     |                     |                    |   |    |    |           |    |    |  |
| *Final Exam         | 60                  |                     |                    | 20  | 15 | 5  | 15        | 5  |    |  |
| *Quizzes            | 15                  |                     |                    |   |    |    | 10        | 5  |    |  |
| *Assignment         | 15                  |                     |                    |   |    |    | 5         |    | 10 |  |
| * presentation      | 10                  |                     |                    |   |    |    |           |    | 10 |  |
| Total out of<br>100 |                     | 100                 |                    | 20  | 15 | 5  | 30        | 10 | 20 |  |

\* Refer to document (CC-2023-03)



Issue Date:11/7/2021

#### **Ninth: Course Polices**

- Meeting the deadline for the lecture.
- Commitment to interaction and participation.
- Interactive lectures will be given through a platform (MS Teams).
- Duties and tests will be given through a platform (Moodle).
- Commitment to the right appearance in front of the camera with the proper background.
- University regulations for attendance and absence from lectures and examinations are in force.
- Academic Integrity: Fraud or moral impersonation are unacceptable and are punishable according to university regulations and instructions.

| Approval              | Name               | Date       | Signature |
|-----------------------|--------------------|------------|-----------|
| Head of<br>Department | Dr. Randa Mansour  | 2024/10/07 |           |
| Faculty Dean          | Dr. Ahlam Alkilani | 2024/10/07 | A         |

